Blood test could guide care for Long-Term breast cancer responders
NCT ID NCT06663787
First seen Jan 09, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study looks at 50 patients with HER2-positive metastatic breast cancer who have had a good response to anti-HER2 therapy for at least two years. Researchers will use a blood test called Signatera to check for tiny bits of cancer DNA. The goal is to learn if this test can help doctors decide whether to continue or stop maintenance treatment in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Nagoya, Aichi-ken, 4678601, Japan
-
Nagoya City University
Nagoya, Aichi-ken, 4678601, Japan
-
Natera
San Carlos, Texas, 94070, United States
-
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Tokyo, Tokyo, 135-8550, Japan
Conditions
Explore the condition pages connected to this study.